The FDA's Prasad Debacle and the Politics of Anti-Establishment Expertise

The administration wanted a credentialed insurgent. What it got was a case study in the limits of governing by disruption.

Dr. Vinay Prasad, the Food and Drug Administration’s controversial vaccine chief, is once again exiting the agency, his second departure in under a year following disputed decisions over vaccine reviews and specialty drugs for rare diseases.

There is something almost touching about the Trump administration’s continuing belief that it can recruit human grenades and then act surprised when someone pulls the pin. That, more or less, is the short political biography of Vinay Prasad at the FDA. Prasad was never some quiet institutional mechanic who might disappear into the wallpaper of federal health regulation, gently sanding rough edges off policy and smiling politely at stakeholder meetings. He built his reputation by being abrasive, skeptical, and conspicuously willing to tell large swaths of the medical establishment that they were lazy, compromised, gullible, or all three. This was not hidden.

And yet the administration appears to have treated him as if he were merely a useful instrument, a critic with enough anti-establishment credibility to satisfy the Covid revisionists, enough scientific vocabulary to keep the whole thing from looking like a total carnival, and enough rhetorical aggression to frighten the old FDA priesthood into submission. What could go wrong, besides the obvious thing that was always going to go wrong?

The obvious thing, to be clear, is that when you hire someone whose public identity is built on detonating consensus, he does not suddenly become a stabilizing steward of a fragile institution. He detonates consensus from the inside. Then everybody involved acts offended that the room now smells like smoke.

Prasad was always an awkward fit for the coalition that brought him in. He was useful to several factions at once, which is not the same thing as being safe with any of them. To the anti-Covid-establishment crowd, he looked like a long-awaited corrective, a doctor with credentials willing to say that public health authorities had oversold certainty, flattened risk differences, and treated boosters like a moral sacrament rather than a policy question. To the performatively heterodox Trump health universe, he looked like proof that the old expert class was finally being forced to answer for itself. To people like Marty Makary, he could be cast as an evidence hawk, someone who would demand better data and tougher scrutiny without going fully feral. To RFK-adjacent vaccine skeptics, he was at least traveling in the right direction, even if he was not one of the true believers.

That is a very flattering way to describe the setup. The less flattering version is that they hired a man who had spent years making enemies in medicine and biotech and then put him in one of the few jobs in Washington where making enemies has immediate consequences for industry, patients, public trust, and internal bureaucratic peace. This was not an unforeseeable mismatch. It was the point of the hire, right up until it became the problem with the hire.

The administration wanted disruption and legitimacy at the same time. It wanted someone who could walk into FDA and signal that the Covid-era public-health consensus was over, that vaccines and biotech products would no longer glide through on old assumptions, and that the cozy little world of expert deference had finally met a man with a flamethrower. At the same time, it wanted all of that to happen in a way that still looked serious, disciplined, and institutionally controlled. It wanted an arsonist who would also serve as fire marshal.

Washington keeps trying this trick, and it keeps failing for the same reason. The people who are good at humiliating institutions in public are not usually the people who are good at making institutions feel calm, predictable, and durable from within. That is not hypocrisy. It is just a job description problem.

Once Prasad had actual power over vaccines and biologics, the contradictions got harder to hide. If you spend years arguing that the FDA is too lax, too deferential, and too willing to bless products on weak evidence, then you cannot arrive in office and immediately govern like some cheerful continuity liberal. You have to make decisions that reflect the brand. That means higher-profile skepticism, more willingness to challenge standard review logic, and more interventions that signal the old equilibrium is over. The Moderna flu-vaccine fight fit this pattern perfectly. So did the controversies around rare-disease products. Whether every underlying scientific objection was right is almost beside the point politically. The point is that he governed like someone hired to prove that the previous regime was broken. Naturally, this made everyone furious.

Industry does not mind strict rules nearly as much as it minds unstable rules. Patients and patient advocates do not mind scientific caution nearly as much as they mind being told that the path they thought existed has suddenly vanished behind a fresh wall of evidentiary purity. Career staff do not mind political appointees existing, because that is normal, but they do tend to mind being dramatically overruled by people who seem intent on turning internal disputes into ideological theater. And populist political coalitions, despite all their noise about truth-telling and shaking things up, are famously thin-skinned when the shaker starts shaking their own preferred outcomes.

That was the real trap. Prasad could not satisfy all the constituencies that briefly found him useful, because those constituencies were never actually aligned. Some wanted better evidence. Some wanted revenge on Covid-era institutions. Some wanted more skepticism of vaccines. Some wanted more flexibility for favored therapies. Some wanted disruption in the abstract but not in any way that harmed their company, cause, or faction. The administration papered over those tensions by imagining that one very combative doctor could somehow embody all of it at once. Instead, they got what they paid for, which is generally how these stories end.

The funniest part, if one can use that word about vaccine regulation and life-or-death biotech decisions, is that the administration did not exactly get betrayed by a hidden saboteur. There was no great reveal. Vinay Prasad turned out to be Vinay Prasad. He arrived with a long public record of antagonism toward medical groupthink, broadside attacks on weak evidence, and a taste for polemical combat. Hiring him and then discovering he was divisive is a bit like adopting a wolf because you admire its independent spirit and then filing a complaint that it seems insufficiently housebroken. And yet that is basically the complaint.

The larger political lesson here is that the Trump administration remains very good at confusing destruction with control. It likes figures who make institutions tremble. It likes the aesthetics of insurgency and the emotional gratification of watching established authorities squirm. But governing agencies is not the same as posting through them. The FDA is not a podcast. It is not a Substack comments section. It is not even cable news, though God knows everyone involved increasingly behaves as if the camera is always on. It is a regulator whose power depends heavily on procedural stability and broad confidence that decisions are not merely factional score-settling in a lab coat.

If you weaken that confidence too much, you do not get a stronger FDA. You get a more political FDA, a less trusted FDA, and a more chaotic market and public-health environment where every decision looks like a referendum on who currently has the commissioner’s ear. That may be emotionally satisfying to people who think the old order deserved humiliation. It is not exactly a recipe for durable governance.

So yes, the administration shot itself in the foot. But only in the sense that it picked up a very conspicuous gun, admired it publicly, pointed it at its own boot, and announced that this time the explosion would be different because the bullet was anti-establishment. It was not different. It was just louder up close.